Matches in SemOpenAlex for { <https://semopenalex.org/work/W2532474449> ?p ?o ?g. }
Showing items 1 to 74 of
74
with 100 items per page.
- W2532474449 endingPage "2001" @default.
- W2532474449 startingPage "2001" @default.
- W2532474449 abstract "2001 Background: KSP is essential for the separation of spindle poles during mitosis and inhibition results in mitotic arrest. Function is thought to be limited to mitosis and inhibitors should not cause the peripheral neuropathy seen with other mitotic-inhibitors. MK-0731 is a potent inhibitor of KSP, with an IC 50 of 2.2 nM, and >20,000 fold selectivity against other kinesins. MK-0731 causes mitotic arrest with an EC 50 in several tumor cell lines of 3−5 nM. Methods: Phase I study to determine the safety and tolerability, MTD, and PK of MK-0731 administered IV over 24 hrs every 21 (Q21) ds. Results: Eight pts with solid tumors (M/F 6/2), median age 55 yrs (45–72 yrs), were treated at doses of 6 to 48 mg/m 2 /24hrs. Prolonged (≥5 ds) Grade 4 neutropenia was observed in 2 pts at 48 mg/m 2 /24 hrs leading to expansion of cohorts at lower dose levels. Other drug related toxicities include diarrhea, alopecia, nail changes, nausea/vomiting, mucositis, abdominal pain, anorexia, phlebitis. PK results suggest that steady-state concentrations may not be achieved by the end of the 24 hr infusion and MK-0731 concentrations appear to decline monoexponentially or biexponentially following the infusion with terminal t 1/2 from ∼4 to 11 hrs. Median values at the 48 mg/m 2 /24 hrs dose level were C max = 1223 nM, AUC∞ = 26.585 μM · hr, and CL=122 mL/min. AUC, exposures, and end of infusion concentrations appear to increase proportionally with dose. Conclusions: This is the first study of MK-0731. The MTD was exceeded at 48 mg/m 2 /24 hrs Q21. Further evaluation will continue at lower doses. [Table: see text]" @default.
- W2532474449 created "2016-10-28" @default.
- W2532474449 creator A5010319264 @default.
- W2532474449 creator A5015092618 @default.
- W2532474449 creator A5027520216 @default.
- W2532474449 creator A5028370411 @default.
- W2532474449 creator A5065343631 @default.
- W2532474449 creator A5071773606 @default.
- W2532474449 creator A5072906560 @default.
- W2532474449 creator A5074861706 @default.
- W2532474449 creator A5080461865 @default.
- W2532474449 date "2006-06-20" @default.
- W2532474449 modified "2023-10-07" @default.
- W2532474449 title "Phase I clinical and pharmacokinetic (PK) trial of the kinesin spindle protein (KSP) inhibitor MK-0731 in cancer patients" @default.
- W2532474449 doi "https://doi.org/10.1200/jco.2006.24.18_suppl.2001" @default.
- W2532474449 hasPublicationYear "2006" @default.
- W2532474449 type Work @default.
- W2532474449 sameAs 2532474449 @default.
- W2532474449 citedByCount "5" @default.
- W2532474449 crossrefType "journal-article" @default.
- W2532474449 hasAuthorship W2532474449A5010319264 @default.
- W2532474449 hasAuthorship W2532474449A5015092618 @default.
- W2532474449 hasAuthorship W2532474449A5027520216 @default.
- W2532474449 hasAuthorship W2532474449A5028370411 @default.
- W2532474449 hasAuthorship W2532474449A5065343631 @default.
- W2532474449 hasAuthorship W2532474449A5071773606 @default.
- W2532474449 hasAuthorship W2532474449A5072906560 @default.
- W2532474449 hasAuthorship W2532474449A5074861706 @default.
- W2532474449 hasAuthorship W2532474449A5080461865 @default.
- W2532474449 hasConcept C112705442 @default.
- W2532474449 hasConcept C126322002 @default.
- W2532474449 hasConcept C197934379 @default.
- W2532474449 hasConcept C2777063308 @default.
- W2532474449 hasConcept C2778375690 @default.
- W2532474449 hasConcept C2778496288 @default.
- W2532474449 hasConcept C2780580376 @default.
- W2532474449 hasConcept C2780852908 @default.
- W2532474449 hasConcept C29730261 @default.
- W2532474449 hasConcept C71924100 @default.
- W2532474449 hasConcept C90924648 @default.
- W2532474449 hasConcept C98274493 @default.
- W2532474449 hasConceptScore W2532474449C112705442 @default.
- W2532474449 hasConceptScore W2532474449C126322002 @default.
- W2532474449 hasConceptScore W2532474449C197934379 @default.
- W2532474449 hasConceptScore W2532474449C2777063308 @default.
- W2532474449 hasConceptScore W2532474449C2778375690 @default.
- W2532474449 hasConceptScore W2532474449C2778496288 @default.
- W2532474449 hasConceptScore W2532474449C2780580376 @default.
- W2532474449 hasConceptScore W2532474449C2780852908 @default.
- W2532474449 hasConceptScore W2532474449C29730261 @default.
- W2532474449 hasConceptScore W2532474449C71924100 @default.
- W2532474449 hasConceptScore W2532474449C90924648 @default.
- W2532474449 hasConceptScore W2532474449C98274493 @default.
- W2532474449 hasIssue "18_suppl" @default.
- W2532474449 hasLocation W25324744491 @default.
- W2532474449 hasOpenAccess W2532474449 @default.
- W2532474449 hasPrimaryLocation W25324744491 @default.
- W2532474449 hasRelatedWork W148728087 @default.
- W2532474449 hasRelatedWork W1979418062 @default.
- W2532474449 hasRelatedWork W2005374976 @default.
- W2532474449 hasRelatedWork W2030053732 @default.
- W2532474449 hasRelatedWork W2033508602 @default.
- W2532474449 hasRelatedWork W2035319767 @default.
- W2532474449 hasRelatedWork W2157228124 @default.
- W2532474449 hasRelatedWork W2330828714 @default.
- W2532474449 hasRelatedWork W2375265431 @default.
- W2532474449 hasRelatedWork W2606466801 @default.
- W2532474449 hasVolume "24" @default.
- W2532474449 isParatext "false" @default.
- W2532474449 isRetracted "false" @default.
- W2532474449 magId "2532474449" @default.
- W2532474449 workType "article" @default.